Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction : MESA
Background Higher fibroblast growth factor-23 ( FGF -23) levels are associated with incident heart failure ( HF ) in MESA (the Multiethnic Study of Atherosclerosis). FGF -23 is also associated with left ventricular hypertrophy. Whether the FGF -23 association with HF is similar for heart failure with reduced ejection fraction ( HF r EF ) and heart failure with preserved ejection fraction ( HF p EF ) is not well established. Methods and Results We studied 6542 participants (mean age 62±10 years, 53% women, mean estimated glomerular filtration rate of 81±18 mL/min per 73 m2) from MESA who were free of cardiovascular disease at baseline (2000-2002). HF events were ascertained by an adjudication committee for a median follow-up of 12.1 years. We classified HF events as HF r EF (ejection fraction [ EF ] <50%) or HF p EF [ EF ] ≥50%) at the time of diagnosis. Cox proportional hazard regression was used to compute hazard ratios and 95% confidence intervals for the association between baseline serum FGF -23 and incident HF r EF and HF p EF . A total of 134 events were classified as HF p EF , 151 HF r EF , and 49 unknown EF . Following imputation, 149 were classified as HF p EF , 176 HF r EF , and 291 participants had HF (34 participants had HF p EF then HF r EF ). In the fully adjusted model, higher FGF -23 levels were associated with incident HF p EF but not with HF r EF (hazard ratio 1.29, 95% confidence interval, 1.08-1.54) versus (hazard ratio 1.04, 95% confidence interval, 0.84-1.29) for each 20 pg/mL higher serum FGF -23 concentration. Conclusions FGF -23 association with HF is driven by the association with HF p EF but not with HF r EF in a population-based cohort. Further studies are needed to determine the pathological mechanisms mediating this association.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Journal of the American Heart Association - 7(2018), 18 vom: 18. Sept., Seite e008334 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Almahmoud, Mohamed Faher [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.11.2019 Date Revised 04.12.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1161/JAHA.117.008334 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM290051584 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM290051584 | ||
| 003 | DE-627 | ||
| 005 | 20231225063905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/JAHA.117.008334 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0966.xml |
| 035 | |a (DE-627)NLM290051584 | ||
| 035 | |a (NLM)30371180 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Almahmoud, Mohamed Faher |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction |b MESA |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2019 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background Higher fibroblast growth factor-23 ( FGF -23) levels are associated with incident heart failure ( HF ) in MESA (the Multiethnic Study of Atherosclerosis). FGF -23 is also associated with left ventricular hypertrophy. Whether the FGF -23 association with HF is similar for heart failure with reduced ejection fraction ( HF r EF ) and heart failure with preserved ejection fraction ( HF p EF ) is not well established. Methods and Results We studied 6542 participants (mean age 62±10 years, 53% women, mean estimated glomerular filtration rate of 81±18 mL/min per 73 m2) from MESA who were free of cardiovascular disease at baseline (2000-2002). HF events were ascertained by an adjudication committee for a median follow-up of 12.1 years. We classified HF events as HF r EF (ejection fraction [ EF ] <50%) or HF p EF [ EF ] ≥50%) at the time of diagnosis. Cox proportional hazard regression was used to compute hazard ratios and 95% confidence intervals for the association between baseline serum FGF -23 and incident HF r EF and HF p EF . A total of 134 events were classified as HF p EF , 151 HF r EF , and 49 unknown EF . Following imputation, 149 were classified as HF p EF , 176 HF r EF , and 291 participants had HF (34 participants had HF p EF then HF r EF ). In the fully adjusted model, higher FGF -23 levels were associated with incident HF p EF but not with HF r EF (hazard ratio 1.29, 95% confidence interval, 1.08-1.54) versus (hazard ratio 1.04, 95% confidence interval, 0.84-1.29) for each 20 pg/mL higher serum FGF -23 concentration. Conclusions FGF -23 association with HF is driven by the association with HF p EF but not with HF r EF in a population-based cohort. Further studies are needed to determine the pathological mechanisms mediating this association | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a ejection fraction | |
| 650 | 4 | |a fibroblast growth factor | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a left ventricular hypertrophy | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a FGF23 protein, human |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factors |2 NLM | |
| 650 | 7 | |a 62031-54-3 |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factor-23 |2 NLM | |
| 650 | 7 | |a 7Q7P4S7RRE |2 NLM | |
| 700 | 1 | |a Soliman, Elsayed Z |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoni, Alain G |e verfasserin |4 aut | |
| 700 | 1 | |a Kestenbaum, Bryan |e verfasserin |4 aut | |
| 700 | 1 | |a Katz, Ronit |e verfasserin |4 aut | |
| 700 | 1 | |a Lima, João A C |e verfasserin |4 aut | |
| 700 | 1 | |a Ouyang, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, P Elliott |e verfasserin |4 aut | |
| 700 | 1 | |a Michos, Erin D |e verfasserin |4 aut | |
| 700 | 1 | |a Herrington, David M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Heart Association |d 2012 |g 7(2018), 18 vom: 18. Sept., Seite e008334 |w (DE-627)NLM222412712 |x 2047-9980 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2018 |g number:18 |g day:18 |g month:09 |g pages:e008334 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/JAHA.117.008334 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2018 |e 18 |b 18 |c 09 |h e008334 | ||